European Journal of Biomedical and Pharmaceutical Sciences

POLYMORPHISM IN THE GLUTHATHIONE S-TRANSFERASE THETA AND MU GENES AND SUSCEPTIBILITY TO LYMPHOID LEUKEMIA IN SUDANESE PATIENTS

Esraa Mohammed Nori* and Ibrahim Khider Ibrahim

ABSTRACT

Background: Glutathione S-transferase (GST) are a family of cytosolic enzymes known to catalyze the detoxification of electrophilic compounds, including carcinogens, therapeutic drugs, environmental toxins, and products of oxidative stress, by conjugation with glutathione. GSTs are able to modulate the induction of other enzymes and proteins important in cellular functions, such as DNA repair, and are therefore important in maintaining genomic integrity and, as a result, may play an important role in cancer susceptibility. Aim: This study aimed to study GSTT1 and GSTM1 null polymorphism in Sudanese patients with lymphoid leukemia (ALL and CLL) and correlate the polymorphism with patients age and gender. Materials and Methods: The study is a case control study, conducted in Khartoum state during the period from Janauary to March 2017 among 20 patients with chronic lymphocytic leukemia among both gender at different ages and 20 patient with acute lymphoctic leukemia and 80 apparently healthy control subjects. The GSTT1 nul genotype was determined using polymerase chain reaction (PCR) method. Results: The GSTT1null polymorphism in patients with acute lymphoid leukemia was detected in 13 of patient (65%) 5of them were male and 8 were females, The GSTM1null polymorphism in patients with acute lymphoid leukemia was detected in 17 of patient (85%) 10of them were male and 7 were females. The GSTT1 null polymorphism was detected in 9 of control(18%) with insignificant(OR=8.5for ALL, 95% CI= (2.6- 27.2 P= 0.00). The GSTM1 null polymorphism was detected in 16 of control (53%) but the difference was statistically significant (OR=0.20for ALL, 95% CI=(0.049- 0.836 P= 0.021). The GSTT1 null polymorphism in patients with chronic lymphocytic leukemia was detected in 7 of patients(35%) 6 of them were male and 1 were females. The GSTM1 null polymorphism in patients with chronic lymphocytic leukemia was detected in 16of patients(80%) 10 of them were male and 6 were females. The GSTT1 null polymorphism was detected in 9 of control(18%) with insignificant (OR=2.4 for cLL, 95% CI=(0.763- 7.890 P= 0.126), The GSTM1 null polymorphism was detected in 16 of control(53%) with significant (OR=0.28 for cLL, 95% CI=(0.077- 1.058 P= 0.054). Conclusion: GSTT1 null genotype is a risk factor for ALL and there is statistically significant association between GSTT1 null polymorphism and ALL.

Keywords: lymphoid leukemia (ALL and CLL), Polymorphism, GSTT1 and GSTM1.